Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
ChinaBio® Today
www.ChinaBioToday.com
ChinaBio® Today is the most widely-read source for China life science news and analysis. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China life science companies and industry events, as well as global issues affecting the China life science industry.

News

< Previous 1 2 3 4 Next >
Yangtze River Pharma Signs $338 Million Deal for Gastro Reflux Therapy
Yangtze River Pharma signed a $338 million deal for China rights to a gastroesophageal reflux treatment from South Korea 's Daewoong Pharma. Fexuprazan is a novel potassium-competitive acid blocker... 
Chance Pharma Acquires China Rights to Inhaled PAH Therapy
Hangzhou Chance Pharma signed a deal with Aerami Therapeutics to acquire greater China rights for a drug device combination product aimed at Pulmonary Arterial Hypertension. Aerami is a North Carolina... 
WuXi Biologics Acquires 90% Stake in CBC's Suzhou CDMO
Shanghai WuXi Biologics will acquire a 90% interest in CMAB Biopharma, a CDMO located in Suzhou . CMAB offers services that range from cell-line development, process development to clinical GMP... 
BeiGene Forms Drug Delivery and Patient Communication Partnership with 111
BeiGene, a Beijing oncology company, will collaborate with Shanghai 's 111 Inc. to develop an Internet + Medicine & Healthcare model to support distribution of BeiGene's products. The companies will... 
Tickers DTP YI
Beijing Tide Out-Licenses Ex-China Rights to Fibrosis Therapy in $518 Million Deal
Beijing Tide Pharma. a subsidiary of Sino Biopharmaceutical, out-licensed ex-China rights for a fibrosis therapy to Graviton Bio of New York in a deal worth up to $517.5 million. TDI01 is a targeted... 
Hansoh Announces $122 Million Agreement to Acquire Rights to Antifungal
ansoh Pharma entered an $122 million agreement to acquire Greater China rights to a novel antifungal from Synexis of New Jersey . The agent, ibrexafungerp, is a first-in-class, broad-spectrum... 
Tickers SCYX
Hansoh Announces $122 Million Agreement to Acquire Rights to Antifungal
ansoh Pharma entered an $122 million agreement to acquire Greater China rights to a novel antifungal from Synexis of New Jersey . The agent, ibrexafungerp, is a first-in-class, broad-spectrum... 
Tickers SCYX
WuXi Biologics Buys Pfizer's Biologics Manufacturing Facility in Hangzhou
Shanghai 's WuXi Biologics, a global CDMO, will acquire a biotech drug manufacturing facility in Hangzhou from Pfizer China . Pfizer completed the facility in 2018 and was using it to manufacture... 
Tickers DS
China Cross-Border Life Science Deals Get 2021 Off to a Fast Start
Just two months into 2021 and it already looks as though the momentum from 2020's record-setting levels of China life science activity continues into the new year. According to data compiled by... 
China Cross-Border Life Science Deals Get 2021 Off to a Fast Start
Just two months into 2021 and it already looks as though the momentum from 2020's record-setting levels of China life science activity continues into the new year. According to data compiled by... 
Adagene Starts Global Trial of CTLA-4 Inhibitor for Solid Tumor Cancers
Adagene, a Suzhou-San Francisco immunotherapy company, has begun dosing patients in a global Phase I trial of ADG126 in patients with advanced solid tumors. ADG126, Adagene’s lead SAFEbody™ product... 
Tickers ADAG
Harbour Bio Starts China Phase III Trial of Novel Dry Eye Treatment
Harbour BioMed has dosed the first patient in the China arm of a global Phase III trial of a novel treatment for moderate-to-severe dry eye disease (DED).  Tanfanercept (HBM9036) is a tumor necrosis... 
Week in Review: Haohai Bio Enters $527 Million Deal for Dermatology Products
Deals and Financings   Shanghai Haohai Biological announced a $527 million agreement to develop Eirion Therapeutics' aesthetic dermatology products in China ; Arctic Vision of Shanghai completed a $100... 
Tickers CASI IMAB
Delonix Bio Raises $14 Million in Seed Financing for Synthetic Vaccines
Shanghai Delonix Bioworks, a startup biotech developing synthetic biology vaccines, closed a $14 million seed financing. Delonix's synthetic biology and antigen discovery platforms are designed to... 
Uni-Bio Partners with DotBio to Develop Retinal Therapeutics
Yangzhou Uni-Bio formed a partnership with Singapore 's DotBio to co-develop next-gen, best-in-class synthetic retinal therapeutics. The companies will use the DotBody platform to generate multiple... 
Kintor's Androgen Agonist Reduces COVID-19 Mortality in Hospitals by 92%
Suzhou Kintor Pharma reported that proxalutamide, its androgen receptor agonist, reduced mortality risk in newly hospitalized COVID-19 patients by 92% (3.7% vs 47.6%). It also shortened median hospital... 
Kintor's Androgen Agonist Reduces COVID-19 Mortality in Hospitals by 92%
Suzhou Kintor Pharma reported that proxalutamide, its androgen receptor agonist, reduced mortality risk in newly hospitalized COVID-19 patients by 92% (3.7% vs 47.6%). It also shortened median hospital... 
I-Mab Forms Two Novel Drug Discovery Collaborations
I-Mab, a Shanghai biopharma, formed two new collaborations, one with Complix of the EU and the other with Shanghai Affinity Biopharma, to discover differentiated drug candidates. Complix's Cell... 
Tickers IMAB
Lee's Pharm Affiliate OK'd for Phase III Trial of PD-L1 for NSCLC
China Oncology Focus (COF), a Lee's Pharm affiliate, was approved to start a China Phase III trial of its anti-PD-L1 antibody as a first-line treatment for non-small cell lung cancer.  In 2014, COF... 
Tickers COF SRNE
Haohai Acquires China Rights to Eirion Dermatology Products in $527 Million Deal
Shanghai Haohai Biological announced a $527 million agreement to develop Eirion Therapeutics' aesthetic dermatology products in China .. Haohai will pay $8 million upfront and make a $32 million... 
Arctic Vision of Shanghai Completes $100 Million Series B Round
Arctic Vision, a Shanghai ophthalmology company, completed a Series B financing of over $100 million led by Loyal Valley Capital. The company has in-licensed greater China rights to three products,... 
BeiGene Starts Trial of HPK1 Inhibitor, a Novel Immunocology Candidate
BeiGene of Beijing started a global Phase I trial of BGB-15025, a novel hematopoietic progenitor kinase 1 (HPK1) inhibitor, in patients with advanced solid tumor cancers. BGB-15025 is a small molecule... 
Alphamab Approved to Start US Trial of PD-L1/CTLA-4 Bispecific
Jiangsu Alphamab Oncology was approved to start a US Phase II trial of its PD-L1/CTLA-4 bispecific antibody in patients with thymic carcinoma, a rare disease. Alphamab said inoperable or metastatic... 
Alphamab Approved to Start US Trials of PD-L1/CTLA-4 Bispecific
Jiangsu Alphamab Oncology was approved to start a US Phase II trial of its  PD-L1/CTLA-4 bispecific antibody in patients with thymic carcinoma, a rare disease. Alphamab said inoperable or metastatic... 
Gannex/Ascletis Reports Positive Phase II Data for NASH Treatment
Shanghai Gannex Pharma, a subsidiary of Hangzhou 's Ascletis, reported positive topline results from the China cohort of a Phase II trial for its nonalcoholic steatohepatitis (NASH) treatment. The... 
Gannex/Ascletis Reports Positive Phase II Data for NASH Treatment
Shanghai Gannex Pharma, a subsidiary of Hangzhou 's Ascletis, reported positive topline results from the China cohort of a Phase II trial for its nonalcoholic steatohepatitis (NASH) treatment. The... 
CASI Acquires China Rights to a p97 Inhibitor for Cancer in $85 Million Deal
CASI Pharma, a Maryland-Beijing in-licensing company, acquired greater China rights to a cancer drug developed by Cleave Therapeutics in an $85 million agreement. CB-5339 is a novel valosin-containing... 
Tickers CASI
WuXi Biologics Out-licenses mAb Panel to Exelixis for Development
WuXi Biologics of Shanghai out-licensed a panel of mAbs to Exelixis aimed at a pre-clinically validated target. Exelixis, a San Francisco area biotech, will use its technology to develop antibody-drug... 
AlphaBio In-licenses Off-the-Shelf NK/T-Cell Technology for Cancer
Shanghai 's AlphaBio in-licensed Asia rights to Wugen's novel universal natural killer (NK) and T-cell therapies for cancer. The agreement will include rights to manufacture universal off-the-shelf... 
Tickers NK
Week in Review: OrbiMed Raises $800 Million for its Fourth Asia Fund
Deals and Financings   OrbiMed Advisors secured $3.5 billion in commitments for its latest capital raise, including $800 million for OrbiMed Asia Partners IV; SciClone Pharma, a Shanghai in-licensing... 
Tickers AZN
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.